Navigation Links
Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Date:10/12/2009

a, including M. tuberculosis, M. avium complex, and M. avium subspecies paratuberculosis, the potential etiological agent of Crohn's disease. SQ641 also has the potential to be effective on additional clinically relevant bacteria. Sequella licensed the compound library from Daiichi-Sankyo (November 2004). Daiichi-Sankyo identified the compound class and performed extensive research and preliminary preclinical development on several drug leads. Sequella has exclusive rights to the series of TL-1 inhibitors for the treatment of TB and all other indications for nearly every worldwide market.

As announced in September 2008, Sequella also received a 3-year, $2.3 Million NIH Phase 2 SBIR grant for development of SQ641 as an antibiotic for treatment of tuberculosis. Approval for funding the 2nd year of this grant, $795,701, was received in early September 2009.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

About the NIH and NIAID

The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
2. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
3. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
4. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
5. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
6. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
7. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
8. Sinovac Obtains Production License for H1N1 Vaccine
9. Blackrock Microsystems Obtains Expanded 510(k) to Market NeuroPort System
10. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
11. NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 LayerBio, Inc., an MIT spinoff ... first round of seed financing from friends and family ... to develop a novel sustained-release product for ophthalmology. , ... and their commitment to this important work," said Dr. ... one of many areas in which innovations in drug ...
(Date:7/29/2014)... technologists have hurdled a number of significant technological ... revolutionary observing technology originally created for the James ... Principal Investigator Harvey Moseley, a scientist at NASA,s ... demonstrated that electrostatically actuated microshutter arrays that ... are as functional as the current technology,s ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... a new way of manufacturing microstructured surfaces that ... self-assembly of carbon nanotubes, could exhibit a variety ... and strength, or the ability to repel water ... that mechanical forces can be used to direct ... we can independently control the mechanical properties ...
Breaking Biology Technology:Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2
... WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology and ... in China and the United,States, today announced that ... Vice,President of Strategy., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Yu worked at Pfizer Inc., where,she co-led Pfizer,s ...
... Archi-Tech Systems, a,leading provider of pharmaceutical ... PromoTrack, a new solution custom-designed to,rapidly measure ... promotions. Archi-Tech has tailored its proven DART ... marketers, seamlessly,integrating disparate promotional campaign and Rx ...
... Inc.,(TSX: SDI) today announced that it has entered ... Medical for Spectral,s Endotoxin,Activity Assay (EAA(TM)), the only ... the terms of the agreement, BB Medical will ... "BB Medical is a leading distributor of medical ...
Cached Biology Technology:WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy 2Pharmaceutical Marketing Done Right: Archi-Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management 2Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay 2
(Date:7/29/2014)... parents of preterm babies latest research from the ... become teenagers, the brains of many preterm children can perform ... study conducted by the University,s Robinson Research Institute ... no brain injury in early life, their cognitive abilities as ... peers. , However, the results of the study, published in ...
(Date:7/28/2014)... approved by the U.S. Food and Drug Administration (FDA) ... certain bacterial pathogens inside human cells, including those that ... findings, published in mBio , the online open-access ... new way of identifying non-antibiotic drugs that could one ... of drugs on the list inhibit the growth of ...
(Date:7/28/2014)... Ariz. - Reactions among minerals and organic compounds in ... carbon cycle, they provide energy for the deep biosphere, ... However, very little is known about how minerals influence ... State University have demonstrated how a common mineral acts ... negating the need for toxic solvents or expensive reagents. ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... for Research in Vision and Ophthalmology (ARVO) is pleased ... recipients will be acknowledged at the ARVO 2012 Annual ... Proctor Medal: Peter Sterling, PhD, Mildred Weisenfeld Award ... FARVO, Cogan Award: Jeffrey L. Goldberg, MD, PhD, Friedenwald ...
... AMHERST, Mass. A team of kinesiology researchers led ... Amherst recently received a 2.5-year, $975,000 grant through the ... to study how the average 100-lb. equipment load carried ... missions, affects their survivability, likelihood of injury and ability ...
... Md. - The first Maryland municipality to earn a ... is the Town of Berlin on the Eastern Shore. ... by the University of Maryland,s Environmental Finance Center - ... as well as revitalize and improve their long-term quality ...
Cached Biology News:2012 ARVO Award recipients honored at annual meeting 2Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2Maryland gets its first 'Certified Sustainable' community: Berlin 2
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
... Removal , , Removes ... cross-reactivity with other proteins , Simple, just ... Economical new surface technology, not based on ... with protein analysis. SurfactAway offers a simple ...
... SDS and Non-ionic Detergent Removal ... , Very selective, virtually no cross-reactivity with ... and discard pellet , Economical new ... , Detergents can often interfere with protein ...
... 3000 workstation automates a wide array of ... Proteomic Sample Preparation to Bio-Molecular and Cell ... of the Caliper Sciclone enables numerous combinations ... meet the needs of a given application, ...
Biology Products: